Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)


ABSTRACT

Purpose
Uveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting. Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent activity in patients with metastatic uveal melanoma in a randomized phase II trial.

Methods
The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial (ClinicalTrial.gov identifier: NCT01974752) in which patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m² intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine. The primary end point was progression-free survival (PFS) by blinded independent central radiologic review. Secondary end points included overall survival and objective response rate.

Results
A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32). In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32). The objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus dacarbazine (two-sided P = .36). At 37% maturity (n = 48 deaths), analysis of overall survival gave a hazard ratio of 0.75 (95% CI, 0.39 to 1.46; two-sided P = .40). The most frequently reported adverse events (selumetinib plus dacarbazine v placebo plus dacarbazine) were nausea (62% v 19%), rash (57% v 6%), fatigue (44% v 47%), diarrhea (44% v 22%), and peripheral edema (43% v 6%).

Conclusion
In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.

J Clin Oncol 36:1232-1239. © 2018 by American Society of Clinical Oncology

INTRODUCTION

Uveal melanoma arises from the uveal tract of the eye, which includes the choroid, ciliary body, and iris, and is the most common primary intraocular malignancy in adults. Uveal melanoma is biologically distinct from cutaneous melanoma and accounts for approximately 3% to 5% of all melanomas in the United States. There are currently no approved or effective systemic therapies specifically for these patients.

Mutations in GNAQ or GNA11 are found in > 80% of uveal melanomas, resulting in constitutive activation of the RAS/RAF/MEK/ERK (RAS-ERK) pathway. Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and highly selective MEK1/2 inhibitor that has a short half-life of approximately 5 hours. In vitro, selumetinib plus temozolomide, an oral prodrug of dacarbazine,
enhanced tumor growth inhibition, DNA damage, and apoptosis in a KRAS-mutant colorectal tumor model compared with temozolomide monotherapy.⁹ In vivo studies demonstrated that selumetinib increases the levels of the proapoptotic protein BIM, a mediator of chemotherapy-induced cell death; therefore, addition of selumetinib to chemotherapy may increase cytotoxicity compared with chemotherapy alone.⁹,¹⁰ Clinical trials assessing efficacy of selumetinib plus chemotherapy have shown activity in patients with mutations associated with the RAS-ERK pathway.¹¹

In an open-label phase II study, patients with metastatic uveal melanoma who had not received prior treatment with temozolomide or dacarbazine achieved improved median progression-free survival (PFS) with selumetinib 75 mg twice daily versus temozolomide or dacarbazine (15.9 v 7 weeks; hazard ratio [HR] 0.46; 95% CI, 0.30 to 0.71; one-sided P < .001).¹²

Building on this evidence, we initiated a phase III trial to assess efficacy and safety of selumetinib plus dacarbazine in patients previously untreated with systemic therapy for metastatic uveal melanoma (Clinicaltrials.gov identifier: NCT01974752).¹³

**Methods**

Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) was a randomized, international, double-blind, placebo-controlled, phase III trial in which patients from 29 centers across 11 countries were enrolled (ClinicalTrials.gov identifier: NCT02768766). The protocol was approved by the local institutional review board or ethics committee of each participating site. The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization. All patients gave informed consent before undergoing any study-specific procedures.

Patients were randomly assigned 3:1 to receive selumetinib or matched placebo, plus dacarbazine, stratified by presence or absence of liver metastases.

**Patients**

Patients were eligible if they had histologically or cytologically confirmed metastatic uveal melanoma, one or more lesions that could be accurately measured using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Patients were excluded if they had previously received systemic anticancer therapy (prior surgery and intrahepatic or other nonsystemic therapies were permitted); history of retinal pigmented epithelial detachment, central serous retinopathy, or retinal vein occlusion in the unaffected eye; or intraocular pressure > 21 mm Hg or uncontrolled glaucoma (irrespective of intraocular pressure) in the unaffected eye.

**Procedures**

Patients received selumetinib (75 mg twice daily, continuous oral administration) or matched placebo, plus dacarbazine (1,000 mg/m² intravenously on day 1 of every 21-day cycle) until objective disease progression (confirmed by blinded independent central review [BICR]), intolerable toxicity, or another discontinuation criterion was met. Upon confirmation of objective disease progression, patients could receive open-label selumetinib monotherapy or selumetinib plus dacarbazine.

All patients were assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) at screening, week 6, and every 6 weeks thereafter until objective disease progression. Tumor response to treatment was assessed by BICR using RECIST 1.1.

Adverse events (AEs) were recorded from the time of informed consent, and graded using the National Cancer Institute Common Terminology Criteria for AEs (version 4.0). Baseline tumor samples from 106 patients were submitted to Foundation Medicine for prospective molecular profiling.

**Study End Points**

The primary end point was efficacy of selumetinib plus dacarbazine compared with placebo plus dacarbazine in terms of PFS assessed by BICR of CT or MRI scans according to RECIST 1.1.¹⁴ Secondary end points included objective response rate (ORR), duration of response, change in tumor size at week 6, overall survival (OS), safety and tolerability, and quality of life. Investigative site-based analysis of PFS was performed as a sensitivity analysis of the primary end point.

**Statistical Analysis**

Assuming a true PFS HR of 0.46,¹² 93 PFS events would provide 90% power to demonstrate a statistically significant difference for PFS at a two-sided significance level of 5%. Approximately 128 patients were required for 3:1 randomization to selumetinib plus dacarbazine (n = 96 patients) or placebo plus dacarbazine (n = 32 patients) groups to obtain a minimum of 93 PFS events. Additional information on randomization, masking, statistical analysis, and procedures is given in the Supplemental Data.

**Results**

**Patients**

From April 2014 to February 2015, 152 patients were screened (Fig 1). Twenty-three patients were excluded and 129 were randomly assigned to either to the study treatment with selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32). Patient demographics were generally balanced between treatment groups at baseline, with the exception of sex and number of sites of disease (Table 1).

**Efficacy**

The primary end point of PFS assessed by BICR was not met. In the selumetinib plus dacarbazine group, there were 82 events (85%) compared with 24 (75%) for placebo plus dacarbazine; the HR for PFS was 0.78 (95% CI: 0.48 to 1.27) with a two-sided P value of 0.32 (Fig 2A), showing no significant benefit of selumetinib plus dacarbazine for PFS. Median estimated PFS was 2.8 months in the selumetinib plus dacarbazine group and 1.8 months in the placebo plus dacarbazine group. Median follow-up for PFS (ie, time from random assignment to death or progression for patients with an event, and time from random assignment to censoring for censored patients) in the selumetinib plus dacarbazine and placebo plus dacarbazine groups was 2.7 and 1.5 months, respectively. Three- and 6-month PFS rates were 38% and 10%, respectively, in the selumetinib plus dacarbazine group, and 26% and 18%, respectively, in the placebo plus dacarbazine group.

The sensitivity analysis of ascertainment bias (based on investigational site-based assessment of PFS) was inconsistent with the primary analysis, showing statistically significant improvement in PFS for selumetinib plus dacarbazine compared with placebo plus dacarbazine (3.8 v 2.1 months; HR, 0.49; 95% CI, 0.28 to 0.84; P = .01; Data Supplement). The sensitivity analysis of evaluation
time bias (based on BICR of CT and MRI scans according to RECIST 1.1) was consistent with the primary analysis (HR, 0.82; 95% CI, 0.51 to 1.33; \( P = .42 \)). The interaction test assessing consistency of treatment effect across potential prognostic factors was statistically significant (\( P = .046; \) Fig 3), mainly due to ECOG performance status, where there was a larger treatment effect in a small subgroup of patients with ECOG performance status of 1 (HR, 0.28; 95% CI, 0.13 to 0.69) compared with ECOG performance status of 0 (HR, 1.03; 95% CI, 0.62 to 1.88). This suggests that patients with a higher tumor burden may have a larger treatment effect; however, no firm conclusions can be made because of the low patient number.

Analysis of the secondary efficacy end points of OS, ORR, and percentage change in tumor size at week 6 showed no statistically significant differences between treatment groups. Preliminary analysis of OS (n = 48 deaths; 37% maturity) by log-rank test gave an HR of 0.75 (95% CI, 0.39 to 1.46; two-sided \( P = .40; \) Fig 2B). Given the results of the primary analysis, additional analysis of OS with additional events is not planned. ORR was similar between the selumetinib plus dacarbazine (n = 3 of 97; 3%) and placebo plus dacarbazine (n = 0 of 32; 0%) groups (two-sided \( P = .36 \)). Three patients achieved partial responses with durations of 43, 56, and 146 days. Target lesion size at week 6 increased in both groups, with patients achieving partial responses with durations of 43, 56, and 56 days in the selumetinib plus dacarbazine group. The majority of these patients (n = 17 of 23) had been randomly assigned to placebo plus dacarbazine in the double-blind phase. Four patients (3%) were receiving ongoing open-label treatment at the time of data cut-off (three patients continued receiving selumetinib monotherapy and one continued receiving selumetinib plus dacarbazine). Disease progression was the most common reason for discontinuation of open-label treatment.

Safety

A summary of AEs is provided in Table 2 and Table 3; AEs of special interest because of their association with selumetinib are highlighted in Table 3. Incidence of AEs of special interest was more frequent with selumetinib plus dacarbazine; however, these were generally grade 1/2. One patient in the selumetinib plus dacarbazine group remained on their randomly assigned study arm. The majority of these patients (n = 17 of 23) had been randomly assigned to placebo plus dacarbazine in the double-blind phase. Four patients (3%) were receiving ongoing open-label treatment at the time of data cut-off (three patients continued receiving selumetinib monotherapy and one continued receiving selumetinib plus dacarbazine). Disease progression was the most common reason for discontinuation of open-label treatment.

Fig 1. CONSORT diagram. Of the 97 patients randomly assigned to receive the combination of selumetinib and dacarbazine, all received the assigned therapy. At the time of data cutoff, 16 continued to receive the assigned study treatment and did not meet criteria for discontinuation. Of the 81 patients who did meet criteria for discontinuation, the subsequent treatment received is listed. Of the 32 patients randomly assigned to receive the combination of placebo and dacarbazine, all received the assigned therapy. At the time of data cutoff, 4 continued to receive the study treatment and did not meet criteria for discontinuation. Of the 28 patients who did meet criteria for discontinuation, the subsequent treatment received is listed. Data cutoff was May 15, 2015.
dacarbazine group, who died of uveal melanoma progression, had grade 5 cardiac failure considered by the investigator to be unrelated to study treatment. Safety and tolerability data from patients receiving open-label therapy were consistent with the mild to moderate toxicities observed during the double-blind phase.

Despite the AE rate, most patients could be treated with single-dose interruptions or reductions. The actual treatment duration of selumetinib or placebo was within 5 days of the intended duration in each group (Table 2), and the actual dose intensity relative to intended dose intensity was > 88% for selumetinib, placebo, and dacarbazine in both groups despite dose reductions or interruptions. The longer treatment with selumetinib was due to longer disease control compared with placebo. Few AEs led to study drug discontinuation; disease progression was the main reason for study drug discontinuation (Table 2).

### Molecular Analysis

Prior groups have demonstrated uveal melanoma to be a disease characterized by a low mutational burden and recurrent chromosomal alterations; however, most of this work has been performed using primary uveal melanoma samples.

Of 106 baseline tumor samples (obtained primarily from metastatic sites of disease) submitted to Foundation Medicine for genomic profiling, 78 were successfully analyzed. There was a median of nine mutations per sample (range, two to 21 mutations). We observed mutually exclusive GNAQ or GNA11 mutations in 94% of samples (n = 73 of 78), a frequency higher than observed in The Cancer Genome Atlas (TCGA) for uveal melanoma data set (Data Supplement). All GNA11 (n = 41 of 41), and most GNAQ mutations (n = 29 of 32) occurred in exon 4; the remaining GNAQ mutations occurred in exon 4 (n = 2). One additional patient had a variant of unknown significance in GNAQ (G48L, exon 2).

Comparison of data from TCGA, reanalyzed using VarDict, showed the most significant difference between SUMIT and TCGA analyses was the incidence of BAP1 mutations, with 62.3% and 30.0% mutation rates, respectively (P = .00006). This is reflective of the increased risk for development of metastatic disease in primary uveal melanomas harboring BAP1 mutations. There were no significant differences for GNA11, GNAQ, or SF3B1 mutations, nor for MYC amplification. CDKN2A/B deletions, GNAS amplification, and TP53 mutations were only detected in the SUMIT cohort and at a low frequency (< 10%). Previous reports have highlighted recurrent mutations in CYSLTR2 and PLCB4, but these were not assessed in this study.

### DISCUSSION

Selumetinib plus dacarbazine did not improve clinical outcomes for patients with metastatic uveal melanoma compared with placebo plus dacarbazine. Although the previous phase II trial of selumetinib monotherapy demonstrated an HR of 0.46 (one-sided P = .001) for PFS in favor of selumetinib over chemotherapy, no significant improvement in PFS was observed with selumetinib plus dacarbazine over placebo plus dacarbazine (HR, 0.78; two-sided P = .32) in this study. Fourteen percent of patients achieved a partial response with selumetinib in the phase II trial, whereas only 3% treated with selumetinib plus dacarbazine achieved a response in the SUMIT trial.

Results of this study differ from others evaluating selumetinib plus chemotherapy in other tumor types characterized by mitogen-activated protein kinase (MAPK) pathway activation, which demonstrate improved clinical activity with combinatorial therapy over chemotherapy alone. These studies also demonstrate how the various mechanisms of MAPK activation can respond differently to MAPK inhibition. In a phase II trial of selumetinib plus dacarbazine versus placebo plus dacarbazine in patients with BRAF-mutant cutaneous or unknown primary melanoma, median PFS was 5.6 and 3.0 months, respectively (HR, 0.63; 80% CI, 0.47 to 0.84; one-sided P = .021), with an ORR of 40% versus 26%. A phase II trial of selumetinib plus docetaxel versus placebo plus docetaxel in patients with KRAS-mutant non–small-cell lung

---

**Table 1. Baseline Characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Selumetinib + Dacarbazine (n = 97), No. (%)</th>
<th>Placebo + Dacarbazine (n = 32), No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>42 (43)</td>
<td>19 (59)</td>
</tr>
<tr>
<td>Male</td>
<td>55 (57)</td>
<td>13 (41)</td>
</tr>
<tr>
<td>Age, years, median (range)</td>
<td>63 (2-86)</td>
<td>58 (42-84)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>96 (99)</td>
<td>31 (97)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (1)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>ECOG PS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>72 (74)</td>
<td>22 (69)</td>
</tr>
<tr>
<td>1</td>
<td>25 (26)</td>
<td>10 (31)</td>
</tr>
<tr>
<td>Primary tumor location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid</td>
<td>86 (89)</td>
<td>29 (91)</td>
</tr>
<tr>
<td>Ciliary body</td>
<td>7 (7)</td>
<td>4 (13)</td>
</tr>
<tr>
<td>Iris</td>
<td>1 (1)</td>
<td>0</td>
</tr>
<tr>
<td>Missing</td>
<td>3 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Presence of liver metastases*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>89 (92)</td>
<td>30 (94)</td>
</tr>
<tr>
<td>No</td>
<td>8 (8)</td>
<td>2 (6)</td>
</tr>
<tr>
<td>Number of organ sites involved with disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>53 (55)</td>
<td>11 (34)</td>
</tr>
<tr>
<td>2</td>
<td>20 (21)</td>
<td>9 (28)</td>
</tr>
<tr>
<td>3</td>
<td>18 (19)</td>
<td>9 (28)</td>
</tr>
<tr>
<td>4</td>
<td>6 (6)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>≥ 5</td>
<td>0</td>
<td>2 (6)</td>
</tr>
<tr>
<td>Time from primary tumor diagnosis to random assignment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 18 months</td>
<td>26 (27)</td>
<td>7 (22)</td>
</tr>
<tr>
<td>&gt; 18 to ≤ 36 months</td>
<td>28 (29)</td>
<td>6 (19)</td>
</tr>
<tr>
<td>&gt; 36 months</td>
<td>43 (44)</td>
<td>18 (56)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Mutation status†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GNAQ mutation positive</td>
<td>23 (28)</td>
<td>9 (28)</td>
</tr>
<tr>
<td>GNA11 mutation positive</td>
<td>33 (42)</td>
<td>8 (22)</td>
</tr>
<tr>
<td>GNAQ and GNA11 mutation negative</td>
<td>4 (7)</td>
<td>1 (3)</td>
</tr>
</tbody>
</table>


*Stratification factor.
†Tumor tissue samples from 106 patients were submitted to Foundation Medicine for genomic profiling; 78 were successfully analyzed; tumor material was insufficient for testing for 28 patients; samples were not available from 23 patients.
cancer demonstrated a median PFS of 5.3 versus 2.1 months, respectively (HR for progression, 0.58, 80% CI, 0.42 to 0.79; one-sided \( P = .014 \)), with an ORR of 37% versus 0%.\(^{19} \) However, more recently, selumetinib plus docetaxel failed to meet the primary end point of PFS in the phase III SELECT-1 trial.\(^{20} \)

Effects of \textit{GNAQ} and \textit{GNA11} mutations on downstream growth pathways differ from those associated with \textit{BRAF} and \textit{KRAS} mutations, and include activation of the MAPK pathway\(^2\) via phospholipase \(C\)\(^2\) and protein kinase \(C\) activation,\(^2\) the phosphatidylinositol-3 kinase (PI3K)/AKT pathway,\(^2\) and the

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Kaplan-Meier estimates of progression-free survival and overall survival. (A) Blinded independent central review of progression-free survival. (B) Overall survival. Population: full analysis set, data cutoff: May 15, 2015. Crosses denote censored observations. Overall survival data are immature, with 34 events (35%) and 14 events (44%) in the selumetinib plus dacarbazine and placebo plus dacarbazine groups, respectively. DTIC, dacarbazine; HR, hazard ratio; Pbo, placebo; Sel, selumetinib.}
\end{figure}

\begin{table}
\centering
\begin{tabular}{|c|c|c|}
\hline
 & Selumetinib + DTIC, No. (%) & Pbo + DTIC, No. (%) & HR (95% CI) \\
\hline
All Patients & 82/97 (85) & 24/32 (75) & 0.80 (0.51 to 1.29) \\
Liver metastases at random assignment & & & \\
Yes & 75/89 (84) & 24/30 (80) & 0.70 (0.45 to 1.14) \\
No (n.c.) & 7/8 (88) & 0/2 (0) & \\
Baseline ECOG PS & & & \\
0 & 61/72 (85) & 16/22 (73) & 1.05 (0.62 to 1.88) \\
1 & 21/25 (84) & 8/10 (80) & 0.28 (0.13 to 0.69) \\
Histology/tumor grade & & & \\
Spindle (n.c.) & 7/8 (88) & 6/8 (75) & \\
Epithelioid & 18/21 (86) & 2/3 (67) & 0.46 (0.13 to 2.92) \\
Mixed & 13/14 (93) & 7/9 (78) & 0.96 (0.39 to 2.55) \\
Unknown & 44/54 (82) & 9/12 (75) & 0.58 (0.30 to 1.27) \\
Sex & & & \\
Male & 47/55 (86) & 12/13 (92) & 0.58 (0.32 to 1.15) \\
Female & 35/42 (83) & 12/19 (63) & 0.92 (0.49 to 1.86) \\
Age at random assignment, years & & & \\
< 65 & 43/51 (84) & 15/20 (75) & 0.83 (0.47 to 1.55) \\
> 65 & 39/46 (85) & 9/12 (75) & 0.80 (0.41 to 1.77) \\
Biomarker & & & \\
\textit{GNA11} positive & 27/33 (82) & 5/8 (62) & 1.28 (0.52 to 3.84) \\
\textit{GNAQ} positive & 20/23 (86) & 9/9 (100) & 0.51 (0.24 to 1.18) \\
Other & 35/41 (86) & 10/15 (66) & 0.88 (0.45 to 1.87) \\
\hline
\end{tabular}
\caption{Progression-free survival by prespecified subgroup. Population: full analysis set, data cutoff: May 15, 2015. Hazard ratios were not calculated for subgroups with < 20 events. With the exception of liver metastases at randomization (yes/no), all analyses were performed using a Cox proportional hazards model. The size of the circle is proportional to the number of events. Progression includes deaths in the absence of RECIST progression. Progression events occurring 14 weeks after last evaluable assessment (or randomization) are censored and, therefore, excluded. DTIC, dacarbazine; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; n.c., not calculated; Pbo, placebo.}
\end{table}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure3.png}
\caption{Progression-free survival by prespecified subgroup. Population: full analysis set, data cutoff: May 15, 2015. Hazard ratios were not calculated for subgroups with < 20 events. With the exception of liver metastases at randomization (yes/no), all analyses were performed using a Cox proportional hazards model. The size of the circle is proportional to the number of events. Progression includes deaths in the absence of RECIST progression. Progression events occurring 14 weeks after last evaluable assessment (or randomization) are censored and, therefore, excluded. DTIC, dacarbazine; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; n.c., not calculated; Pbo, placebo.}
\end{figure}
Hippo pathway.\textsuperscript{25} This, as well as other cell context–dependent differences between uveal melanoma, \textit{BRAF}-mutant cutaneous melanoma, and \textit{KRAS}-mutant non–small-cell lung cancer, in part may explain the discrepant results observed in these trials; however, additional investigation into these differences is needed. Limited work conducted in parallel to the SUMIT trial in three xenograft models derived from patients with uveal melanoma, derived from metastatic tumor specimens and characterized by \textit{GNAQ} and \textit{GNA11} mutations, demonstrated that dacarbazine alone and in combination with selumetinib induced strong tumor growth inhibition in one model, and selumetinib continued after combination treatment significantly delayed disease progression compared with dacarbazine maintenance. However, combination of selumetinib and dacarbazine did not increase tumor response in these models compared with either agent alone, comparable to the results observed in the SUMIT trial.\textsuperscript{26} These xenograft models derived from patients with uveal melanoma were difficult to generate; therefore, these data were not available at the time of trial design.

Median PFS in this study was 2.8 months in the selumetinib plus dacarbazine group, numerically but not statistically greater than the 1.8 month median PFS observed in the placebo plus dacarbazine group. Given the 6-week interval for restaging studies in this trial, these results are comparable to the PFS of 3.6 months observed in the selumetinib monotherapy group and 1.6 months observed in the chemotherapy group in the phase II monotherapy trial, during which imaging was performed every 4 weeks for 8 weeks, and every 8 weeks thereafter. It was hypothesized that the lack of significant benefit for selumetinib plus dacarbazine in this study may have been caused by increased toxicity, decreased compliance, or decreased dose density. However, the actual treatment duration for selumetinib or placebo being within 5 days of the intended treatment duration in each group, and the actual dose intensity relative to intended dose intensity > 88% for each treatment across both groups, provides evidence against this hypothesis.

The modest improvement in PFS observed with selumetinib alone or plus dacarbazine in uveal melanoma suggests that any clinical activity of MEK inhibitors in G-protein–driven tumors may be limited by the rapid development of adaptive resistance to MEK inhibition or progression of primarily resistant tumor clones. This hypothesis is supported by the results of the phase III trial of binimetinib, an oral selective adenosine triphosphate–uncompetitive inhibitor of MEK1/2 versus dacarbazine in \textit{NRAS}-mutant cutaneous melanoma, where, despite an overall response rate of 15% with binimetinib, demonstrating objective radiographic evidence of antitumor activity, only a modest improvement in median PFS of 2.8 versus 1.5 months in favor of binimetinib was reported (HR, 0.62; 95% CI, 0.47 to 0.80; \( P = .001 \)).\textsuperscript{27}

Radiographic assessment of treatment response in liver metastases is associated with unique challenges, with interobserver agreement dependent on radiologist experience and the imaging modality used.\textsuperscript{28} These challenges are amplified in uveal melanoma, a disease with a predilection for hepatic metastasis and associated with greater radiographic heterogeneity compared with other tumor types as a result of the presence of hemorrhage, methemoglobin, and melanin.\textsuperscript{29} These factors may have contributed to the discordance in our results based on central and site-based radiologic reviews. Although the HR for the primary analysis of PFS assessed by BICR was a statistically insignificant 0.78 in favor of selumetinib plus dacarbazine (two-sided \( P = .32 \)), the HR of PFS assessed by investigative site–based review was 0.49 in favor of selumetinib plus dacarbazine (two-sided \( P = .01 \)), with a median PFS of 3.8 versus 2.1 months in the selumetinib plus dacarbazine and placebo plus dacarbazine groups, respectively. In 88 of the 106 patients (83%) with PFS events, there was concordance between central and site-based imaging reviews regarding the development of disease progression; however, a difference was observed in the timing of progression events, which was the primary driver in the difference in PFS as determined by central and site-based reviews. Despite the double-blinded study design and the use of independent reference radiologists for review of imaging studies at most of the participating centers, the distinct toxicity profile associated with selumetinib that includes easily observable toxicities such as rash, peripheral edema, and creatine phosphokinase elevation may have introduced bias into the site-based determination of PFS.

In conclusion, selumetinib plus dacarbazine was not associated with a significant improvement in PFS or ORR for patients with metastatic uveal melanoma compared with placebo plus dacarbazine. Given the lack of effective treatment options for patients with advanced uveal melanoma, rapid development and testing of novel therapeutic strategies are critical. The SUMIT trial began 6 years after initial reports of frequent, functionally activating \textit{GNAQ} mutations in uveal melanoma and demonstrates feasibility of the rapid conduct of pivotal clinical trials in this rare tumor type. Despite the results of this study, additional assessment of MEK inhibitors in uveal
melanoma is warranted. It remains a possibility that dacarbazine limits the efficacy of MEK inhibitors in this disease, and the exploration of selumetinib as monotherapy or in alternative combinations, other than with alkylating agents, remains of interest. A trial evaluating selumetinib plus paclitaxel for metastatic uveal melanoma is underway (EudraCT: 2014-004437-22). On the basis of the hypotheses that greater efficacy and improved tolerability may be achieved by delivering selumetinib in greater doses, with more complete target inhibition using a pulsatile dosing schedule, a phase Ib dose-escalation study of intermittent selumetinib in patients with advanced uveal melanoma who have not been previously treated with a MEK inhibitor is also ongoing (ClinicalTrials.gov: NCT02768766).

Table 3. Most Frequent Adverse Events (All Causality) Reported in ≥ 10% of Patients During Randomized Treatment

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Selumetinib + Dacarbazine (n = 97)</th>
<th>Placebo + Dacarbazine (n = 32)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any Grade</td>
<td>Grade 3</td>
</tr>
<tr>
<td>Patient with any adverse event</td>
<td>97 (100)</td>
<td>47 (48)</td>
</tr>
<tr>
<td>Nausea*</td>
<td>60 (62)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Rash*</td>
<td>55 (57)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Fatigue*</td>
<td>43 (44)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Diarrhea*</td>
<td>43 (44)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Peripheral edema*</td>
<td>42 (43)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Constipation</td>
<td>37 (38)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Dermatitis aceriform*</td>
<td>30 (31)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Vomiting*</td>
<td>27 (28)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Anemia</td>
<td>21 (22)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>19 (20)</td>
<td>0</td>
</tr>
<tr>
<td>Hypertension*</td>
<td>18 (19)</td>
<td>8 (8)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>17 (18)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Anemia</td>
<td>17 (18)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Stomatitis*</td>
<td>15 (16)</td>
<td>0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>14 (14)</td>
<td>0</td>
</tr>
<tr>
<td>Headache</td>
<td>13 (13)</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>12 (12)</td>
<td>0</td>
</tr>
<tr>
<td>Skin fissures</td>
<td>12 (12)</td>
<td>0</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>11 (11)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>11 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>11 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Dry skin*</td>
<td>11 (11)</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>10 (10)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Vision blurred*</td>
<td>10 (10)</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia*</td>
<td>9 (9)</td>
<td>0</td>
</tr>
<tr>
<td>Insomnia</td>
<td>7 (7)</td>
<td>0</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (5)</td>
<td>0</td>
</tr>
</tbody>
</table>

Note. Population: safety analysis set, data cutoff: May 15, 2015. Adverse events reported in ≥ 10% patients, ordered by frequency in patients receiving selumetinib plus dacarbazine.

*Adverse event of special interest because of known association with selumetinib.
†Deterioration compared with baseline in protocol-mandated laboratory values were reported as adverse events if they fulfilled any of the serious adverse event criteria or were the reason for discontinuation of treatment with the investigational product.
‡Creatinine phosphokinase increase was prospectively measured in the battery of laboratory parameters.

Conception and design: Richard D. Carvajal, Gary K. Schwartz, Paul Nathan


Data analysis and interpretation: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

Disclosures provided by the authors are available with this article at jco.org.
References


Affiliations

Richard D. Carvajal and Gary K. Schwartz, Columbia University Medical Center; Paul B. Chapman and Alexander N. Shoushtari, Memorial Sloan Kettering Cancer Center, New York, NY; Sophie Piperno-Neumann and Manuel J. Rodrigues, Institut Curie, Paris; Lauris Gastaud, Centre Antoine-Lacassagne, Nice, France; Ellen Kapiteijn, Leiden University Medical Center, Leiden, the Netherlands; Stephen Frank, Hebrew University Hadassah Medical School – The Sharet Institute of Oncology, Jerusalem; Jacob Schachter, Sheba Medical Center at Tel Hashomer, and Tel-Aviv University Medical School, Tel Aviv, Israel; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Josep M. Pliualts, Institut Catala d’Oncologia L’Hospitalet, L’Hospitalet de Llobregat, Barcelona, Spain; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Veronique Cocquyt, Ghent University Hospital, Ghent, Belgium; Bartosz Chmielowski, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA; T.R. Jeffry Evans, University of Glasgow, Glasgow; Delyth Clennett, Shirley Spratt, Susan Lovick, and Elaine Kilgour, AstraZeneca, Macclesfield; Dana Ghiorghi and Gabriella Mariani, AstraZeneca, Cambridge; Paul Nathan, Mt Vernon Cancer Centre, Northwood, United Kingdom; Gerald Linette, Washington University School of Medicine, St Louis, MO; Carola Berking, University Hospital of Munich, Munich, Germany; Peter Barker, AstraZeneca, Gaithersburg, MD; and Zhongwu Lai, AstraZeneca, Waltham, MA.

Support

Supported by AstraZeneca.

Prior Presentation

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rcw or ascopubs.org/jco/site/icf.

Richard D. Carvajal
Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Foundation Medicine, Iconic Therapeutics, Immunocore, Incyte, Merck, Roche
Other Relationship: Aura Biosciences, Chimeron, Rgenix

Sophie Piperno-Neumann
No relationship to disclose

Paul B. Chapman
Honoraria: Bristol-Myers Squibb, GlaxoSmithKline, Roche, Proventus, Momenta Pharmaceuticals, Daiichi Sankyo
Consulting or Advisory Role: Bristol-Myers Squibb, GlaxoSmithKline, Roche, Daiichi Sankyo, Proventus, Momenta Pharmaceuticals
Research Funding: GlaxoSmithKline, Roche, Bristol-Myers Squibb, Pfizer
Travel, Accommodations, Expenses: Bristol-Myers Squibb

Stephen Frank
No relationship to disclose

Paul Nathan
Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb, MSD, Immunocore, Pfizer, Pierre Fabre
Stock or Other Ownership: Bristol-Myers Squibb, MSD
Travel, Accommodations, Expenses: Bristol-Myers Squibb, MSD

Carola Berking
Honoraria: Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Amgen, Pierre Fabre
Consulting or Advisory Role: Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche, Amgen, Sanofi/Regeneron, Pierre Fabre, AstraZeneca, Incyte, Merck Serono
Travel, Accommodations, Expenses: Amgen, Merck Sharp & Dohme

Jacob Schachter
No relationship to disclose

Manuel J. Rodrigues
Honoraria: AstraZeneca
Consulting or Advisory Role: AstraZeneca
Research Funding: Bristol-Myers Squibb, Merck Sharp & Dohme

Alexander N. Shoushtari
Consulting or Advisory Role: Vaccinex, Castle Biosciences, Immunocore, Bristol-Myers Squibb
Research Funding: Bristol-Myers Squibb, Immunocore, Xcovery
Travel, Accommodations, Expenses: Bristol-Myers Squibb

Delyth Clemett
Employment: AstraZeneca
Stock or Other Ownership: AstraZeneca

Shirley Spratt
Employment: AstraZeneca
Stock or Other Ownership: AstraZeneca

Susan Lovick
Employment: AstraZeneca
Stock or Other Ownership: AstraZeneca

Peter Barker
Employment: AstraZeneca
Stock or Other Ownership: AstraZeneca

Elaine Kilgour
Employment: AstraZeneca
Stock or Other Ownership: AstraZeneca

Zhongwu Lai
Employment: AstraZeneca
Stock or Other Ownership: AstraZeneca

Gary K. Schwartz
No relationship to disclose

Paul Nathan
Consulting or Advisory Role: AstraZeneca, Bristol-Myers Squibb, MSD, Immunocore, Pfizer, Pierre Fabre, Novartis, GlaxoSmithKline, Ipsen
Speakers’ Bureau: Bristol-Myers Squibb, Novartis
Travel, Accommodations, Expenses: Bristol-Myers Squibb, MSD
Acknowledgment

We thank the patients, investigators, and institutions that were involved in this study. Medical writing services were provided by Jon Moran, of iMed Comms, an Ashfield Company, part of UDG Healthcare, and were funded by AstraZeneca.